Barcelona, Spain-based AELIX Therapeutics’s proprietary T-cell immunogen has shown a signal of therapeutic benefit in an early clinical study, and the biotech is now aiming to raise series B financing to support further development of the vaccine.
The pharmaceutical/biotech industry has a long history of disappointing attempts to successfully develop HIV prophylactic and therapeutic vaccines, but Aelix believes the design characteristics of its proprietary immunogen, HTI, which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?